SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) therapies.
Biogen/Elan's Tysabri has been under scrutiny due to two additional reported cases of PML, a rare and potentially fatal brain disease associated with use of the drug. MedPredict recently convened an expert panel of neurologists to assess the significance of the PML cases, and the effect on prescribing and development of new potent immunosurveillants.
"Nobody at the Thought Leader level was surprised that there were more new (PML) events," according to Jeff Berk, MedPredict's president. "At the time of the reinstatement of the US license for Tysabri, the FDA Advisory Committee stated that they expected there to be more events. Our panel discusses whether that sentiment will translate to community-based neurologists."
The report also updates progress on other approaches to treatment of MS, including:
-- New interferons, integrin inhibitors, B-cell inhibitors, S1Ps, fumarates, neuroprotection/neuroregeneration.
-- The potential for vaccine or MAb approaches for the treatment or prevention of multiple sclerosis.
-- Which therapeutics in development to provide symptomatic benefits in MS are the most likely winners.
MedPredict's analysis also provides guidance for clinical trial design in MS. "There have been a number of high-profile failed trials, both in relapsing-remitting and in progressive MS," said Dr. Berk. "The panel talks about strategies for improving the odds of success through better designs and better metrics."
Companies and partnerships discussed in this report include: Acorda,
Amgen/Epix, Artielle ImmunoTherapeutics, Avanir, BaroFold, Bayhill,
Bayer-Schering, Bayer-Schering/Genzyme, Biogen, Biogen/Ela
Copyright©2008 PR Newswire.
All rights reserved